The Zacks Analyst Blog Highlights: Yahoo, Google, Microsoft, Wright Medical and ArthroCare Corporation

News provided by

Jul 19, 2011, 09:30 ET

CHICAGO, July 19, 2011 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Yahoo! Inc. (Nasdaq: YHOO), Google Inc (Nasdaq: GOOG), Microsoft Corp (Nasdaq: MSFT), Wright Medical (Nasdaq: WMGI) and ArthroCare Corporation (Nasdaq: ARTC).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Monday's Analyst Blog:

Earnings Preview: Yahoo!

Yahoo! Inc. (Nasdaq: YHOO) is expected to report second quarter results after the market closes on July 19. Given the strong ad market, we expect a moderate beat.

Yahoo's story is tied to CEO Carol Bartz's turnaround plan; therefore, with things going rather slow on that front, there are limited catalysts to drive estimates either up or down. That said, the company has delivered an average earnings surprise of over 16% in the last four quarters, which is not bad, considering the multiple issues facing Yahoo right now.

Bartz had waxed eloquent about Yahoo's leadership in display and where it intended to go from there. And indeed, Yahoo! remains an important player in the display market, with the largest share at big advertisers. With market research firms projecting that display will continue to grow in importance over the next few years, overtaking search advertising revenue by 2015, Yahoo! should see good growth in the area.

However, there are a couple of factors that will likely work against it. The first is the growing importance of Google Inc's (Nasdaq: GOOG) display network, which has steadily expanded the market in the SMB segment and enabled it to displace Yahoo! as the biggest player in the overall display ad market. We think there is limited satisfaction in the fact that Yahoo! remains well positioned at the big players. The writing appears to be on the wall.

The second thing that could work very rapidly to eat its share is the growing importance of social networking platforms, particularly Facebook. Facebook is already picking up a good amount of ads and since the platform encourages sharing of personal preferences and choices, ad placements are likely to be well targeted. Unlike Google, which has been very focused on its social efforts (however badly bungled in the past), we have not seen major initiatives from the Yahoo! camp.

Search remains a weak spot for Yahoo!, although management continues to emphasize the fact that engagement on Yahoo! properties is up. The fact remains it lost market share in June, with Google grabbing half of it and Microsoft Corp (Nasdaq: MSFT) picking up the rest. The search alliance is on, but way behind schedule. Monetization efforts are below expectations although advertisers are seeing good ROI. We think the bottom line counts at this point, although the payment plans are favorable for Yahoo! and provide some downside risk.

With the top line trudging along less than smoothly, Yahoo! has necessarily been disciplined on the bottom line. Expense control has been great, and we expect this to remain a focus area.

Another much hyped driver remains the company's Asian assets, which are of dubious value in our opinion, since much seems to be going on in both Japan and China, with the end result being assurances of "progress".

At any rate, given the above, we are hardly surprised that there have been practically no estimate revisions in the last 30 days, with the Zacks Consensus Estimates for the June quarter and fiscal 2011 remaining exactly where they were at 18 and 79 cents, respectively. Estimates for 2012 also remain unchanged at 91 cents, clearly indicating that analysts are not expecting any miracles.

The Zacks Rank on Yahoo! shares is #3 (Hold rating over the next 1-3 months). We are also Neutral over the long term (3-6 month timeframe).

Wright & ArthroCare Join Hands

International orthopedic devices company Wright Medical (Nasdaq: WMGI) has inked a supply and distribution pact with surgical products maker ArthroCare Corporation (Nasdaq: ARTC). Under the agreement, ArthroCare will provide Wright Medical with products for soft tissue fixation of the foot and ankle based on its Opus knotless suturing technology.

The deal covers a range of tissue fixation devices, based on the market-leading Opus technology, which Wright Medical will exclusively distribute to foot and ankle surgeons globally. Wright Medical plans to market these products during second-half 2011 through its dedicated foot and ankle sales team.

Austin-based ArthroCare develops and markets minimally-invasive, state-of-the-art surgical products, addressing a multi-billion dollar market opportunity across several medical specialties. Its proprietary Opus technology enables surgeons to effectively fix tendons and ligaments to bony structures without the need to tie knots. The company's fixation technology is widely used in the rotator cuff repair market, having been used in more than 100,000 procedures globally since 2001.

Wright Medical is a global orthopedic devices company specializing in the development and marketing of reconstructive joint devices and bio-orthopedic materials. It is a leader in the U.S. and German markets for foot and ankle surgical products.

Wright Medical's market-leading foot and ankle product line includes the CHARLOTTE reconstructive implants, DARCO locked plating systems, the INBONE total ankle replacement system and the latest INBONE II total ankle replacement system.

We feel future revenue growth will be supported by new product launches. Moreover, new deals in extremities, Wright Medical's fastest growing segment, are expected to bolster growth in this business.

Our views are moderated by intense competition from larger players, pricing pressure, and a still soft U.S. orthopedic reconstruction market. We are currently Neutral on the stock.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
[email protected]
http://www.zacks.com

SOURCE Zacks Investment Research, Inc.